Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Et studie af tolerabilitet, sikkerhed og effektivitet af asciminib hos patienter med Philadelphia-kromosom-positiv kronisk myeloid leukæmi i kronisk fase i Tyskland (ASC2ADHERE)

5. november 2026 opdateret af: Novartis Pharmaceuticals

En ikke-interventionsundersøgelse af tolerabiliteten, sikkerheden og effektiviteten af Asciminib hos nydiagnosticerede og tidligere behandlede patienter med Philadelphia-kromosom-positiv kronisk myeloid leukæmi i kronisk fase i Tyskland - ASC2ADHERE-studiet

The aim of this study is to assess the real-world effectiveness of asciminib in Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP) patients who were either newly diagnosed or previously treated with one ATP-competitive tyrosine kinase inhibitor (TKI).

Studieoversigt

Status

Rekruttering

Undersøgelsestype

Observationel

Tilmelding (Anslået)

380

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Undersøgelse Kontakt Backup

  • Navn: Novartis Pharmaceuticals

Studiesteder

      • Amberg, Tyskland, 92224
        • Rekruttering
        • Novartis Investigative Site
      • Bad Friedrichshall, Tyskland, 74177
        • Rekruttering
        • Novartis Investigative Site
      • Bad Liebenwerda, Tyskland, 04924
        • Rekruttering
        • Novartis Investigative Site
      • Bad Saarow, Tyskland, 15526
        • Rekruttering
        • Novartis Investigative Site
      • Berlin, Tyskland, 10437
        • Rekruttering
        • Novartis Investigative Site
      • Berlin, Tyskland, 10365
        • Rekruttering
        • Novartis Investigative Site
      • Berlin, Tyskland, 12552
        • Rekruttering
        • Novartis Investigative Site
      • Berlin, Tyskland, 10559
        • Rekruttering
        • Novartis Investigative Site
      • Berlin, Tyskland, 12487
        • Rekruttering
        • Novartis Investigative Site
      • Bremerhaven, Tyskland, 27568
        • Rekruttering
        • Novartis Investigative Site
      • Buchholz Nordheide, Tyskland, 21244
        • Rekruttering
        • Novartis Investigative Site
      • Cottbus, Tyskland, 03046
        • Rekruttering
        • Novartis Investigative Site
      • Deggendorf, Tyskland, 94469
        • Rekruttering
        • Novartis Investigative Site
      • Detmold, Tyskland, 32756
        • Rekruttering
        • Novartis Investigative Site
      • Dorfen, Tyskland, 84405
        • Rekruttering
        • Novartis Investigative Site
      • Dortmund, Tyskland, 44263
        • Rekruttering
        • Novartis Investigative Site
      • Dresden, Tyskland, 01307
        • Rekruttering
        • Novartis Investigative Site
      • Dresden, Tyskland, 01127
        • Rekruttering
        • Novartis Investigative Site
      • Düren, Tyskland, 52353
        • Rekruttering
        • Novartis Investigative Site
      • Erfurt, Tyskland, 99085
        • Rekruttering
        • Novartis Investigative Site
      • Erfurt, Tyskland, 99084
        • Rekruttering
        • Novartis Investigative Site
      • Eschweiler, Tyskland, 52249
        • Rekruttering
        • Novartis Investigative Site
      • Göttingen, Tyskland, 37073
        • Rekruttering
        • Novartis Investigative Site
      • Hanover, Tyskland, 30161
        • Rekruttering
        • Novartis Investigative Site
      • Hanover, Tyskland, 30625
        • Rekruttering
        • Novartis Investigative Site
      • Hildesheim, Tyskland, 31135
        • Rekruttering
        • Novartis Investigative Site
      • Kiel, Tyskland, 24105
        • Rekruttering
        • Novartis Investigative Site
      • Leipzig, Tyskland, 04103
        • Rekruttering
        • Novartis Investigative Site
      • Leverkusen, Tyskland, 51375
        • Rekruttering
        • Novartis Investigative Site
      • Mutlangen, Tyskland, 73557
        • Rekruttering
        • Novartis Investigative Site
      • Naunhof, Tyskland, 04683
        • Rekruttering
        • Novartis Investigative Site
      • Neuss, Tyskland, 41462
        • Rekruttering
        • Novartis Investigative Site
      • Offenburg, Tyskland, 77654
        • Rekruttering
        • Novartis Investigative Site
      • Oldenburg, Tyskland, 26121
        • Rekruttering
        • Novartis Investigative Site
      • Parchim, Tyskland, 19370
        • Rekruttering
        • Novartis Investigative Site
      • Potsdam, Tyskland, 14467
        • Rekruttering
        • Novartis Investigative Site
      • Potsdam, Tyskland, 14482
        • Rekruttering
        • Novartis Investigative Site
      • Schorndorf, Tyskland, 73614
        • Rekruttering
        • Novartis Investigative Site
      • Schwetzingen, Tyskland, 68723
        • Rekruttering
        • Novartis Investigative Site
      • Soest, Tyskland, 59494
        • Rekruttering
        • Novartis Investigative Site
      • Stade, Tyskland, 21680
        • Rekruttering
        • Novartis Investigative Site
      • Torgau, Tyskland, 04860
        • Rekruttering
        • Novartis Investigative Site
      • Ulm, Tyskland, 89081
        • Rekruttering
        • Novartis Investigative Site
      • Wetzlar, Tyskland, 35578
        • Rekruttering
        • Novartis Investigative Site
    • Baden-Wurttemberg
      • Baden-Baden, Baden-Wurttemberg, Tyskland, 76532
        • Rekruttering
        • Novartis Investigative Site
      • Heidenheim, Baden-Wurttemberg, Tyskland, 89522
        • Rekruttering
        • Novartis Investigative Site
      • Schwäbisch Hall, Baden-Wurttemberg, Tyskland, 74523
        • Rekruttering
        • Novartis Investigative Site
      • Winnenden, Baden-Wurttemberg, Tyskland, 71364
        • Rekruttering
        • Novartis Investigative Site
    • Bavaria
      • Aschaffenburg, Bavaria, Tyskland, 63739
        • Rekruttering
        • Novartis Investigative Site
      • Augsburg, Bavaria, Tyskland, 86152
        • Rekruttering
        • Novartis Investigative Site
      • Donauwörth, Bavaria, Tyskland, 86609
        • Rekruttering
        • Novartis Investigative Site
      • Herrsching am Ammersee, Bavaria, Tyskland, 82211
        • Rekruttering
        • Novartis Investigative Site
      • Kempten (Allgäu), Bavaria, Tyskland, 87439
        • Rekruttering
        • Novartis Investigative Site
      • Landsberg am Lech, Bavaria, Tyskland, 86899
        • Rekruttering
        • Novartis Investigative Site
      • Munich, Bavaria, Tyskland, 81241
        • Rekruttering
        • Novartis Investigative Site
      • Munich, Bavaria, Tyskland, 81377
        • Rekruttering
        • Novartis Investigative Site
      • Regensburg, Bavaria, Tyskland, 93053
        • Rekruttering
        • Novartis Investigative Site
    • Free Hanseatic City of Bremen
      • Bremerhaven, Free Hanseatic City of Bremen, Tyskland, 27576
        • Rekruttering
        • Novartis Investigative Site
    • Hesse
      • Kassel, Hesse, Tyskland, 34125
        • Rekruttering
        • Novartis Investigative Site
      • Offenbach, Hesse, Tyskland, 63065
        • Rekruttering
        • Novartis Investigative Site
    • Lower Saxony
      • Goslar, Lower Saxony, Tyskland, 38642
        • Rekruttering
        • Novartis Investigative Site
      • Rotenburg (Wümme), Lower Saxony, Tyskland, 27356
        • Rekruttering
        • Novartis Investigative Site
      • Twistringen, Lower Saxony, Tyskland, 27239
        • Rekruttering
        • Novartis Investigative Site
    • North Rhine-Westphalia
      • Cologne, North Rhine-Westphalia, Tyskland, 50674
        • Rekruttering
        • Novartis Investigative Site
      • Cologne, North Rhine-Westphalia, Tyskland, 50677
        • Rekruttering
        • Novartis Investigative Site
      • Cologne, North Rhine-Westphalia, Tyskland, 51103
        • Rekruttering
        • Novartis Investigative Site
      • Solingen, North Rhine-Westphalia, Tyskland, 42653
        • Rekruttering
        • Novartis Investigative Site
      • Wesel, North Rhine-Westphalia, Tyskland, 46483
        • Rekruttering
        • Novartis Investigative Site
    • Saxony
      • Zittau, Saxony, Tyskland, 02763
        • Rekruttering
        • Novartis Investigative Site
    • Saxony-Anhalt
      • Halle, Saxony-Anhalt, Tyskland, 06110
        • Rekruttering
        • Novartis Investigative Site
      • Merseburg, Saxony-Anhalt, Tyskland, 06217
        • Rekruttering
        • Novartis Investigative Site
    • Schleswig-Holstein
      • Oldenburg in Holstein, Schleswig-Holstein, Tyskland, 23758
        • Rekruttering
        • Novartis Investigative Site
    • Thuringia
      • Altenburg, Thuringia, Tyskland, 04600
        • Rekruttering
        • Novartis Investigative Site
      • Saalfeld, Thuringia, Tyskland, 07318
        • Rekruttering
        • Novartis Investigative Site

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år til 100 år (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Prøveudtagningsmetode

Ikke-sandsynlighedsprøve

Studiebefolkning

Adult Ph+ CML-CP patients, either newly diagnosed or previously treated with one ATP-competitive TKI, who initiate TKI treatment as recommended by the treating physician in a hematology center in Germany.

Beskrivelse

Inclusion criteria:

  1. Written informed consent must be obtained before participation in the study/prior to any study-related documentation.
  2. Adult patients (≥18 years of age) with a confirmed diagnosis of Ph+ CML-CP. The presence of the Philadelphia chromosome may alternatively be confirmed by molecular detection of a BCR::ABL1 fusion gene/transcript (e.g., by reverse transcription polymerase chain reaction (RT-PCR)), in accordance with the World Health Organization (WHO) 2022 classification.
  3. Patients who are either newly diagnosed or have received treatment with exactly one prior TKI. Prior TKI treatment is only permitted for patients in the Asciminib Cohort. Patients in the comparator cohorts (imatinib, dasatinib, bosutinib, nilotinib) must be newly diagnosed and must not have received any prior TKI treatment.
  4. Patients for whom the treating physician has made a clinical decision to initiate treatment with asciminib or another TKI (imatinib, dasatinib, bosutinib, nilotinib) as part of routine care. The clinical decision for treatment must have been made prior to enrollment. Treatment must not have started more than 14 days before study inclusion, and treatment may also begin after baseline assessment.
  5. Patients willing to participate in routine follow-up visits and complete patient-reported outcome questionnaires over the course of the study.

Exclusion criteria:

  1. Patients with contraindications to their respective chronic myeloid leukemia (CML) treatment as per the applicable Summary of Product Characteristics (SmPC) and relevant national treatment guidelines (e.g. Onkopedia CML), as well as additional disease- or treatment-related characteristics associated with distinct clinical scenarios that differ from the intended study population, including situations with specific treatment requirements or limited comparability, in which reliable interpretation of study outcomes may not be feasible, including the following asciminib specific considerations:

    • In first- or second-line treatment: presence of BCR::ABL1 fusion transcripts lacking exon a2 (e.g. e13a3, e14a3, e1a3).

    • In second-line treatment:

      • known BCR::ABL1 mutations associated with partial or complete resistance to asciminib (e.g. M244V, F359I/V/C).
      • presence of the BCR::ABL1 T315I mutation, regardless of eligibility for treatment according to SmPC (e.g., specific indication and dosing regimens).
  2. Patients receiving or planned to receive asciminib or other TKIs outside the approved label (off-label use), including use in unapproved dosing regimens or frequency not covered by the respective SmPC.

  3. Patients currently participating in an interventional clinical trial.

  4. Patients unable or unwilling to provide written informed consent.

  5. Patients who are unable to reliably complete patient-reported outcome questionnaires due to cognitive or language limitations relevant to the study assessments.

  6. Patients for whom long-term follow-up is not feasible due to expected relocation or other logistical constraints.

  7. The restriction to a maximum of one prior ATP-competitive TKI applies exclusively to patients treated with asciminib. Patients in the comparator cohorts (imatinib, dasatinib, bosutinib, nilotinib) must be TKI-naïve and are included at the start of their first-line TKI therapy and are not eligible if they have received any prior TKI treatment.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Observationsmodeller: COHORT
  • Tidsperspektiver: PROSPECTIVE

Kohorter og interventioner

Gruppe / kohorte
Asciminib Cohort

Adult patients with Ph+ CML-CP, either newly diagnosed or previously treated with one TKI, who are treated with asciminib.

Imatinib Cohort

Adult patients newly diagnosed with Ph+ CML-CP treated with imatinib who have not received any prior TKI treatment.

Second-generation TKI Cohort

Adult patients newly diagnosed with Ph+ CML-CP treated with dasatinib, bosutinib, or nilotinib who have not received any prior TKI treatment.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Percentage of Patients With Major Molecular Response (MMR) at 12 Months
Tidsramme: Month 12

MMR is defined as a BCR::ABL1 level ≤ 0.1% according to the International Scale (IS).

Month 12

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Procentdel af patienter efter årsag til TKI-behandlingsbeslutning dokumenteret af den behandlende læge
Tidsramme: Baseline
Baseline
Andel patienter med dosisreduktion efter årsag til dosisreduktion
Tidsramme: 3, 6, 9, 12, 15, 18, 21 og 24 måneder
3, 6, 9, 12, 15, 18, 21 og 24 måneder
Procentdel af patienter med behandlingsafbrydelse efter årsag til afbrydelsen
Tidsramme: 3, 6, 9, 12, 15, 18, 21 og 24 måneder
3, 6, 9, 12, 15, 18, 21 og 24 måneder
Procentdel af patienter, der afbrød behandlingen efter årsag til afbrydelse
Tidsramme: 3, 6, 9, 12, 15, 18, 21 og 24 måneder
3, 6, 9, 12, 15, 18, 21 og 24 måneder
Tid til behandlingsophør
Tidsramme: 3, 6, 9, 12, 15, 18, 21 og 24 måneder
3, 6, 9, 12, 15, 18, 21 og 24 måneder
Tid til behandlingsafbrydelse
Tidsramme: 3, 6, 9, 12, 15, 18, 21 og 24 måneder
3, 6, 9, 12, 15, 18, 21 og 24 måneder
Tid til dosisreduktion
Tidsramme: 3, 6, 9, 12, 15, 18, 21 og 24 måneder
3, 6, 9, 12, 15, 18, 21 og 24 måneder
Tid til behandlingsophør på grund af bivirkninger (TTDAE)
Tidsramme: 3, 6, 9, 12, 15, 18, 21 og 24 måneder
3, 6, 9, 12, 15, 18, 21 og 24 måneder
Percentage of Patients by Clinical Characteristic
Tidsramme: Baseline

Characteristics include, but are not limited to, detection of Philadelphia chromosome or BCR::ABL1 transcript, prior treatment, and Eastern Cooperative Oncology Group (ECOG) performance status.

Baseline
Percentage of Patients With Early Molecular Response (EMR) at 3 Months
Tidsramme: Month 3

EMR is defined as BCR::ABL1 ≤10% IS.

Month 3
Percentage of Patients With Molecular Response 2 (MR2)
Tidsramme: 3, 6, 9, 12, 15, 18, 21, and 24 months

MR2 is defined as BCR::ABL1 ≤1% IS.

3, 6, 9, 12, 15, 18, 21, and 24 months
Percentage of Patients With MMR
Tidsramme: 3, 6, 9, 15, 18, 21, and 24 months

MMR is defined as BCR::ABL1 ≤0.1% IS.

3, 6, 9, 15, 18, 21, and 24 months
Percentage of Patients With Deep Molecular Response: MR4.0
Tidsramme: 3, 6, 9, 12, 15, 18, 21, and 24 months

Deep Molecular Response (MR4.0): ≤0.01% BCR::ABL1 IS and Reference gene copies >10,000 ABL1 or >24,000 GUSB.

3, 6, 9, 12, 15, 18, 21, and 24 months
Percentage of Patients With Deep Molecular Response: MR4.5
Tidsramme: 3, 6, 9, 12, 15, 18, 21, and 24 months

Deep Molecular Response (MR4.5): ≤0.0032% BCR::ABL1 IS and Reference gene copies >32,000 ABL1 or >77,000 GUSB.

3, 6, 9, 12, 15, 18, 21, and 24 months
Percentage of Patients With Deep Molecular Response: MR5
Tidsramme: 3, 6, 9, 12, 15, 18, 21, and 24 months

Deep Molecular Response (MR5): ≤0.001% BCR::ABL1 IS and Reference gene copies >100,000 ABL1 or >240,000 GUSB.

3, 6, 9, 12, 15, 18, 21, and 24 months
Medication Adherence Report Scale (MARS-5) Score
Tidsramme: 3, 6, 9, 12, 15, 18, 21, and 24 months

The MARS-5 questionnaire is a validated self-report questionnaire developed to assess patient adherence to prescribed medication, focusing on both intentional and unintentional non-adherence. It consists of 5 items, each rated on a 5-point Likert Scale from 0 (always) to 5 (never). The total score ranges from 5 to 25, with higher scores indicating better adherence to treatment.

3, 6, 9, 12, 15, 18, 21, and 24 months
European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (EORTC QLQ-C30) Score
Tidsramme: 3, 6, 9, 12, 15, 18, 21, and 24 months

The EORTC QLQ-C30 contains 30 questions answered by the patient. There are 9 multiple-item scales: 5 scales that assess aspects of functioning (physical, role functioning, cognitive, emotional, and social); 3 symptom scales (fatigue, pain, and nausea and vomiting); and a global health status/Quality of Life (QOL) scale. There are 5 single-item measures assessing additional symptoms (i.e., dyspnea, loss of appetite, insomnia, constipation, and diarrhea) and a single item concerning perceived financial impact of the disease. All but 2 questions have 4-point scales ranging from "Not at all" to "Very much." The 2 questions concerning global health status/QOL have 7-point scales with ratings ranging from "Very poor" to "Excellent." For each of the 14 domains, final scores are transformed such that they range from 0-100, where higher scores indicate improvement.

3, 6, 9, 12, 15, 18, 21, and 24 months
European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire for CML (EORTC QLQ-CML24) Score
Tidsramme: 3, 6, 9, 12, 15, 18, 21, and 24 months

The EORTC QLQ-CML24 was designed to supplement the QLQ-C30 - the QLQ-CML24 is not a stand-alone instrument but is to be used in conjunction with the QLQ-C30.

The EORTC QLQ-CML24 is composed of 4 multi-item scales and 2 single-item scales. The module consists of 24 items assessing symptom burden (13 items), impact on worry/mood (4 items), impact on daily life (3 items), satisfaction with care and information (2 items) body image problems (1 item) and satisfaction with social life (1 item). The items are measured on 4 levels: 1=not at all, 2=a little, 3=quite a bit, 4=very much. For each domain, scores are averaged and transformed to 0 to 100.

A higher score in symptom burden, impact on worry/mood, impact on daily life, and body image problems domains indicates a worse outcome. A higher score in satisfaction with social life and satisfaction with care and information domains indicates a higher level of satisfaction.

3, 6, 9, 12, 15, 18, 21, and 24 months
Work Productivity and Activity Impairment - General Health (WPAI-GH) Score
Tidsramme: 3, 6, 9, 12, 15, 18, 21, and 24 months

The WPAI-GH is a patient-reported 6 item questionnaire which addresses absenteeism, presenteeism, overall work productivity loss, and activity impairment for the 7 days prior to the assessment. Work productivity and activity impairment outcomes are presented as impairment percentages ranging from 0 to 100 with a higher percentage indicating greater impairment and less productivity.

3, 6, 9, 12, 15, 18, 21, and 24 months

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Efterforskere

  • Studieleder: Novartis Pharmaceuticals, Novartis Pharmaceuticals

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

17. april 2026

Primær færdiggørelse (Anslået)

30. september 2030

Studieafslutning (Anslået)

30. september 2030

Datoer for studieregistrering

Først indsendt

16. april 2026

Først indsendt, der opfyldte QC-kriterier

16. april 2026

Først opslået (Faktiske)

24. april 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

9. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

5. november 2026

Sidst verificeret

1. november 2026

Mere information

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner